Lb Pharmaceuticals Common Stock Net Income
| LBRX Stock | 22.53 0.15 0.67% |
As of the 28th of January, LB Pharmaceuticals owns the Standard Deviation of 4.98, mean deviation of 3.73, and Market Risk Adjusted Performance of (0.99). In connection with fundamental indicators, the technical analysis model lets you check timely technical drivers of LB Pharmaceuticals Common, as well as the relationship between them.
LB Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing LB Pharmaceuticals' valuation are provided below:We have found ninety-three available fundamental measures for LB Pharmaceuticals, which can be analyzed and compared to other ratios and to its peers in the sector. All investors should make sure to check all of LB Pharmaceuticals latest market performance against the performance between 2010 and 2026 to make sure the company can sustain itself this quarter and beyond. Enterprise Value is likely to rise to about 55.8 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -56.8 M | -54 M | |
| Net Loss | -56.8 M | -54 M | |
| Net Loss | (20.50) | (19.48) | |
| Net Income Per E B T | 1.15 | 1.10 |
LBRX | Net Income | Build AI portfolio with LBRX Stock |
Latest LB Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of LB Pharmaceuticals Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in LB Pharmaceuticals Common financial statement analysis. It represents the amount of money remaining after all of LB Pharmaceuticals Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is LB Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LB Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (63.1 M) | 10 Years Trend |
|
Net Income |
| Timeline |
LBRX Net Income Regression Statistics
| Arithmetic Mean | (21,567,354) | |
| Coefficient Of Variation | (81.36) | |
| Mean Deviation | 12,840,465 | |
| Median | (14,348,000) | |
| Standard Deviation | 17,546,494 | |
| Sample Variance | 307.9T | |
| Range | 56.8M | |
| R-Value | (0.61) | |
| Mean Square Error | 205.8T | |
| R-Squared | 0.37 | |
| Significance | 0.01 | |
| Slope | (2,122,792) | |
| Total Sum of Squares | 4926.1T |
LBRX Net Income History
Other Fundumenentals of LB Pharmaceuticals Common
LB Pharmaceuticals Net Income component correlations
LBRX Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for LB Pharmaceuticals is extremely important. It helps to project a fair market value of LBRX Stock properly, considering its historical fundamentals such as Net Income. Since LB Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of LB Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of LB Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LB Pharmaceuticals. If investors know LBRX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about LB Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of LB Pharmaceuticals Common is measured differently than its book value, which is the value of LBRX that is recorded on the company's balance sheet. Investors also form their own opinion of LB Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is LB Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because LB Pharmaceuticals' market value can be influenced by many factors that don't directly affect LB Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between LB Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if LB Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, LB Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
LB Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to LB Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of LB Pharmaceuticals.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in LB Pharmaceuticals on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding LB Pharmaceuticals Common or generate 0.0% return on investment in LB Pharmaceuticals over 90 days. LB Pharmaceuticals is related to or competes with Rocket Pharmaceuticals, Aura Biosciences, Annexon, Solid Biosciences, Larimar Therapeutics, Altimmune, and Autolus Therapeutics. LB Pharmaceuticals is entity of United States More
LB Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure LB Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess LB Pharmaceuticals Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.01 | |||
| Information Ratio | 0.118 | |||
| Maximum Drawdown | 23.59 | |||
| Value At Risk | (6.59) | |||
| Potential Upside | 9.38 |
LB Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for LB Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as LB Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use LB Pharmaceuticals historical prices to predict the future LB Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1071 | |||
| Jensen Alpha | 0.7022 | |||
| Total Risk Alpha | 0.1885 | |||
| Sortino Ratio | 0.1467 | |||
| Treynor Ratio | (1.00) |
LB Pharmaceuticals January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1071 | |||
| Market Risk Adjusted Performance | (0.99) | |||
| Mean Deviation | 3.73 | |||
| Semi Deviation | 3.57 | |||
| Downside Deviation | 4.01 | |||
| Coefficient Of Variation | 746.68 | |||
| Standard Deviation | 4.98 | |||
| Variance | 24.78 | |||
| Information Ratio | 0.118 | |||
| Jensen Alpha | 0.7022 | |||
| Total Risk Alpha | 0.1885 | |||
| Sortino Ratio | 0.1467 | |||
| Treynor Ratio | (1.00) | |||
| Maximum Drawdown | 23.59 | |||
| Value At Risk | (6.59) | |||
| Potential Upside | 9.38 | |||
| Downside Variance | 16.04 | |||
| Semi Variance | 12.78 | |||
| Expected Short fall | (4.35) | |||
| Skewness | 0.7121 | |||
| Kurtosis | 0.7218 |
LB Pharmaceuticals Common Backtested Returns
LB Pharmaceuticals appears to be somewhat reliable, given 3 months investment horizon. LB Pharmaceuticals Common retains Efficiency (Sharpe Ratio) of 0.13, which conveys that the company had a 0.13 % return per unit of price deviation over the last 3 months. By analyzing LB Pharmaceuticals' technical indicators, you can evaluate if the expected return of 0.67% is justified by implied risk. Please exercise LB Pharmaceuticals' Standard Deviation of 4.98, market risk adjusted performance of (0.99), and Mean Deviation of 3.73 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, LB Pharmaceuticals holds a performance score of 10. The firm owns a Beta (Systematic Risk) of -0.66, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning LB Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, LB Pharmaceuticals is likely to outperform the market. Please check LB Pharmaceuticals' potential upside, and the relationship between the jensen alpha and accumulation distribution , to make a quick decision on whether LB Pharmaceuticals' current price history will revert.
Auto-correlation | 0.43 |
Average predictability
LB Pharmaceuticals Common has average predictability. Overlapping area represents the amount of predictability between LB Pharmaceuticals time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of LB Pharmaceuticals Common price movement. The serial correlation of 0.43 indicates that just about 43.0% of current LB Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.43 | |
| Spearman Rank Test | 0.41 | |
| Residual Average | 0.0 | |
| Price Variance | 1.59 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
LBRX Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, LB Pharmaceuticals Common reported net income of (63.1 Million). This is 118.49% lower than that of the Healthcare sector and 190.09% lower than that of the Biotechnology industry. The net income for all United States stocks is 111.05% higher than that of the company.
LBRX Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses LB Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of LB Pharmaceuticals could also be used in its relative valuation, which is a method of valuing LB Pharmaceuticals by comparing valuation metrics of similar companies.LB Pharmaceuticals is currently under evaluation in net income category among its peers.
LBRX Fundamentals
| EBITDA | (63.01 M) | ||||
| Net Income | (63.1 M) | ||||
| Total Debt | 3.7 M | ||||
| Cash Flow From Operations | (53.05 M) | ||||
| Number Of Employees | 16 | ||||
| Total Asset | 33.53 M | ||||
| Retained Earnings | (104.32 M) | ||||
| Working Capital | 20.77 M | ||||
| Net Asset | 33.53 M |
About LB Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze LB Pharmaceuticals Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of LB Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of LB Pharmaceuticals Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| HITI | High Tide | |
| HITI | High Tide | |
| BAC | Bank of America |
Additional Tools for LBRX Stock Analysis
When running LB Pharmaceuticals' price analysis, check to measure LB Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LB Pharmaceuticals is operating at the current time. Most of LB Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of LB Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LB Pharmaceuticals' price. Additionally, you may evaluate how the addition of LB Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.